74.55
-1.675(-2.20%)
Currency In USD
Address
125 Strafford Avenue
Wayne, PA 19087
United States of America
Phone
484 253 1461
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
January 02, 2015
| Name | Title | Pay | Year Born |
| Mr. Wesley H. Kaupinen | Founder, President, Chief Executive Officer & Director | 901,066 | N/A |
| Dr. Jeffrey Martini Ph.D. | Chief Scientific Officer | 530,435 | 1978 |
| Ms. Kathleen Goin | Chief Operating Officer | 638,960 | 1971 |
| Ms. Emily Cook | Senior Vice President of Clinical Operations | 0 | N/A |
| Mr. Jason Burdette | SVice President of CMC & Technical Operations | 0 | N/A |
| Mr. Matthew E. Korenberg | Chief Financial Officer & Treasurer | 0 | 1975 |
| Ms. Bohan Wei | Vice President of Corporate Development & New Product Planning | 0 | N/A |
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.